NVST
Envista Holdings Corporation
Healthcare · Medical Instruments & Supplies · NYQ
$23.10
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$3.8B
Total market value of the company
56.85
Expensive — high growth expected
14.85
Based on estimated future earnings — lower means cheaper
Rev Growth
+14.4%
Year-over-year revenue change
Profit Margin
2.4%
How much profit the company keeps from each dollar of revenue
2.2%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$31.00
+34% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 13 analysts covering this stock
About Envista Holdings Corporation

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

https://envistaco.com

Country: United States Employees: 12,000 Industry: Medical Instruments & Supplies
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

DISTRIBUTION
Smart money appears to be selling into strength — caution
0.525
Good returns relative to risk taken
0.0358
Modest edge detected — smaller position warranted
0.417
Drawdown risk outweighs the returns — higher risk profile
Annual Return
14.1%
Historical annualised return based on price data
-33.9%
Largest peak-to-trough decline — the worst it has been
CRISIS
Elevated risk detected — extreme caution warranted
Days in State
14
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.93
Less volatile than the market — more defensive
52W High
$30.42
24% below the year high
52W Low
$17.78
30% above the year low
Avg Volume
2,911,808
Average daily shares traded — higher means easier to buy and sell
3.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
7.9%
Moderate short interest
N/A
Annual dividend as a percentage of the share price
$0.41
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

51.61
Heavy leverage — higher financial risk if revenues decline
2.44
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
1.93
Like current ratio but excludes inventory — stricter test
Gross Margin
55.3%
Revenue left after cost of goods — higher means pricing power
Operating Margin
9.9%
Profit from core operations before interest and tax
$216M
Positive — the business generates more cash than it spends
Revenue (TTM)
$2.8B
Total revenue over the last 12 months
Net Income
$68M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
13
Target High
$35.00
Target Median
$31.00
Target Low
$21.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.